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Abstract: In vivo body exposure therapy is considered an effective and suitable intervention to help
patients with anorexia nervosa (AN) reduce their body image disturbances (BIDs). However, these
interventions have notable limitations and cannot effectively reproduce certain fears usually found
in AN, such as the fear of gaining weight (FGW). The latest developments in virtual reality (VR)
technology and embodiment-based procedures could overcome these limitations and allow AN
patients to confront their FGW and BIDs. This study aimed to provide further evidence of the efficacy
of an enhanced (by means of embodiment) VR-based body exposure therapy for the treatment of
AN. Thirty-five AN patients (16 in the experimental group, 19 in the control group) participated in
the study. FGW, BIDs, and other body-related and ED measures were assessed before and after the
intervention and three months later. The experimental group received treatment as usual (TAU) and
five additional sessions of VR-based body exposure therapy, while the control group received only
TAU. After the intervention, ED symptoms were clearly reduced in both groups, with most of the
changes being more noticeable in the experimental group. Specifically, after the intervention and at
follow-up, significant group differences were found in the FGW and BIDs, with the experimental
group showing significantly lower values than the control group. The current study provides new
insights and encouraging findings in the field of exposure-based therapies in AN. VR technology
might improve research and clinical practice in AN by providing new tools to help patients confront
their core fears (i.e., food- or weight-related cues) and improve their emotional, cognitive, and
behavioral responses to their body image.
Keywords: eating disorders; virtual reality body exposure; fear of gaining weight; body image
disturbances; anorexia nervosa
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1. Introduction
Eating disorders (ED) are severe disorders characterized by dysfunctional patterns
in eating or weight-control behaviors that affect the individual’s physical and mental
health [1]. Anorexia nervosa (AN) is one of the most severe types of EDs, affecting approxi-
mately 1–4% of European women and 0.3–0.7% of men [2]. It has higher mortality rates
than other EDs and psychopathologies, with one in five deaths resulting from suicide [3,4].
Furthermore, AN is increasingly being diagnosed in younger patients [5,6], with a typical
age of onset of around 14 and 19 years [7,8]. Some studies report that approximately 40%
of new AN cases are diagnosed during early adolescence or adolescence [3,5].
One of the main core fears among individuals with AN is the fear of gaining weight
(FGW). The FGW is an overconcern and an extreme fear of the possibility of gaining weight
in the whole body or in some specific body parts, even at a significantly low weight [1,9].
Individuals with AN may also display dysfunctional behaviors that aim to avoid weight
gain by any means possible (e.g., by drastically reducing food intake, vomiting, using
laxatives and diuretics, or doing intense exercises, etc.) [1].
The FGW level reported by AN patients may vary during the disorder or during
treatment. For instance, some patients experience a significant increase in FGW levels after
a small weight restoration in an ED inpatient unit. This, a small degree of positive weight
gain activates a series of catastrophic beliefs based on continuous and uncontrollable weight
gain expectations, which in turn lead to an exponential increase in FGW levels [10]. A recent
study using network analyses found that most ED symptoms/pathology can be explained
not by the unique effect of gaining weight, but by the negative associated consequences
that patients usually report [11]. Based on this last assumption, it has been proposed that
the extinction of the FGW in AN does not solely occur via a progressive habituation process
towards weight recovery, but also via mechanisms of the inhibitory learning systems [10].
Thus, the FGW construct can be also understood as a feared outcome/consequence, and
individuals presenting a great FGW can learn new healthy associations with their own
weight and silhouette when their threatening weight-related expectations are not met (e.g.,
if I increase my weight . . . I will not resist it, people are going to laugh at me or tell me that
I am fat, etc.).
Several studies have suggested a direct relationship between the FGW and greater
ED symptomatology [12,13], indicating that the FGW is a core mechanism underlying AN
symptomatology. Indeed, recent studies have found that the FGW is directly associated
with overvaluing the body and feeling guilty after overeating [14], with the FGW being the
strongest predictor of ED symptomatology (e.g., dietary restraint) in AN patients [15].
Individuals with AN also present body image disturbances (BIDs), which are cog-
nitive and emotional disturbances in the way in which one’s body weight or shape is
experienced [16] (Legenbauer, Thiemann, and Vocks, 2014). Body image distortion (the per-
ceptual component) and body image dissatisfaction (the affective component) are the most
studied BIDs [17,18]. Individuals with EDs, particularly AN, usually display a series of
avoidance behaviors and negative checking strategies towards their own body, which lead
to a dysfunctional body-related attention or attentional bias (AB; [19,20]). Previous studies
suggest that body-related AB may be an important factor maintaining BIDs in patients with
EDs and healthy individuals [20–22]. For instance, individuals who are very dissatisfied
with some of their body areas (i.e., the thighs) tend to focus their attention repeatedly
and constantly on those specific body areas, which may trigger and reinforce a series of
negative body-related beliefs (e.g., my thighs are getting fatter) that lead to higher body
dissatisfaction levels [20]. Furthermore, previous research has found that body-related AB
seems to be especially pronounced in adolescent patients with restrictive AN [23].
Several studies have suggested the necessity to implement specific tailored inter-
ventions that aim to decrease fears and other body-related disturbances. This has led
to improvements in evidence-based therapies (i.e., cognitive behavioral therapy, CBT)
in AN and other EDs [10,24–28]. Exposure-based therapies provide a good example of
interventions targeting specific food- and body-related fears, such as the FGW in AN [27].
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Previous studies have presented promising results for exposure-based therapies conducted
as part of CBT or as a separate intervention [28–30].
Among the exposure-based procedures using body image cues, mirror exposure
therapy (MET) has been widely used. This usually involves the patient systematically
observing their body or specific body parts for a certain amount of time [31,32] in a
neutral descriptive way (non-judgmental MET; [33]), a positive descriptive way (cognitive
dissonance-based MET; [34]), or in a freely descriptive way, with the individual freely
expressing their emotions and thoughts about their body (pure MET; [35]). Pure MET has
been shown to be the most effective in reducing body dissatisfaction [35].
MET has already been successfully used as a complement to AN treatment [36], re-
ducing negative body-related emotions and cognitions through a habituation process [37].
However, more research is needed with randomized controlled clinical trials involving
larger sample sizes and follow-up results [29]. In-vivo mirror and body exposure tech-
niques may be difficult to implement in severe cases of AN; due to the risk of eliciting
habituation toward an extremely low weight (or very skinny body shape), they may be
contraindicated in these patients [38,39]. Other studies emphasize the need to implement
body shape interventions during intensive hospitalization treatment programs in AN [40].
The application of new technologies such as virtual reality (VR) could provide innovative
solutions to some of the previous problems.
VR is a transformative technology that has been widely used in the last decade to
improve exposure-based therapies. It is associated with improved treatment adherence
and acceptance rates compared to in vivo exposure therapy [41]. VR technology can be also
used to create highly realistic simulations of everyday life situations associated with the
patients’ body or weight concerns, as well as three-dimensional (3D) avatars that reproduce
the patients’ silhouettes based on their own body size, skin, height, and clothes [42,43].
Furthermore, VR technology now allows individuals to be “embodied” in a virtual
avatar, or in other words, to perceive and regard a virtual body as their own real body,
experiencing the illusion of owning the virtual body [44] in what is known as full body
illusion (FBI). FBI is defined as the subjective experience in which individuals regard an
artificial body as their own body by combining different types of information (visual,
acoustic, proprioceptive, vestibular, etc.) into different multisensory representations [45,46].
One of the most studied body ownership paradigms is the rubber hand illusion [47].
The continuing improvements in VR embodiment-based techniques have produced
new applications for improving health-related issues in a transdisciplinary research field
known as embodied medicine [48,49]. Previous research on body image has already
demonstrated that VR embodiment-based procedures can modify and even improve
BIDs [40]. For instance, these techniques can change the perception of the whole body or
specific body parts among healthy participants [46,50,51] and patients with EDs [52–54].
While most of the in-vivo body exposure-based therapies, such as MET and VR-based
interventions, have focused on treating BIDs, little information is available about the use
of body exposure techniques, with or without VR, to treat the FGW. Imaginal exposure
might help patients with AN confront their core FGW, which is impractical to do with other
techniques. Two studies have presented very encouranging results for imaginal exposure:
a case report [55] and a clinical study with a large sample of patients with EDs [56]. The
latter study reported that after conducting four weekly sessions of online and self-guided
imaginal exposure, ED symptoms and ED-related fears significantly decreased after the
therapy and at the six-month follow-up [56]. That study provided the first evidence of
the effectiveness and usefulness of imaginal exposure techniques in reducing fears and
ED-related symptomatology. However, some patients who undergo imaginal exposure
might report difficulties by achieving or maintaining a visualization over time, and may
also display avoidance-based strategies while they imagine their most feared stimulus
during visualization (e.g., visualizing a progressive weight gain). VR technology can
overcome these limitations, since it does not rely on the visualization ability of the patient
(e.g., while patients own their real-size virtual body, they can experience a weight gain in a
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more vivid way). In addition, this technology can significantly reduce avoidance-based
behaviors, for instance, by using eye-tracking (ET) devices on the VR-HMD to control the
patient’s gaze patterns towards their own body.
To date, there has been only one case report discussing the use of a VR embodiment-
based paradigm in targeting the FGW in AN. In that case report, a patient with AN
underwent a structured exposure intervention owning a virtual body that simulated their
own body, leading to an increase in the BMI until a healthy BMI was obtained. In that
report, there was a decrease in the FGW and related ED symptomatology after five sessions
of VR body exposure therapy [54].
Based on these promising results, the current study aimed to go further and provide
additional evidence of the usefulness of a VR body exposure therapy in AN (hereinafter
referred to as AN-VR-BE) in directly targeting the FGW and other body-related disturbances
using a larger sample and a controlled experimental design. In particular, the current study
aimed to assess the effectiveness of AN-VR-BE through a randomized controlled clinical
trial (clinicaltrials.gov (accessed on 1 January 2021), NCT 04028635), in which patients
with AN were evaluated before and after the intervention, and three months later. The
starting hypothesis was that if a component of body exposure through VR (intensified
through an illusion of virtual body ownership) was added to the usual treatment for
AN (experimental group), the treatment would be more effective than usual treatment
only (TAU, the control group). It was expected that after comparing measures before and
after the treatment, and three months later, the experimental group (AN-VR-BE + TAU)
would show a significant increase in BMI values alongside significant reductions in FGW
levels, other ED symptomatology, and body-related AB when compared to the control
group (TAU).
2. Materials and Methods
2.1. Clinical Sample
Thirty-five adolescent and adult patients with AN participated in the study. All the
patients were randomly assigned to the two groups: 16 patients were assigned to the
experimental group and 19 patients to the control group. Most of the patients were women,
with only four men in the sample who were split equally between the two groups. All
the adolescent patients received treatment at the ED Unit of Hospital Sant Joan de Déu of
Barcelona. Adult patients received treatment at the ED Units of the Hospital of Bellvitge
and Hospital Clínico San Carlos of Madrid. All patients were diagnosed in their respective
ED Units.
All patients diagnosed with AN using the DSM-5 criteria [1], aged 13 years or over,
with a BMI < 19, and able to understand and read Spanish were invited to participate
in the study. One patient who did meet all the DSM-5 criteria for AN except for two
also participated in the study. The exclusion criteria were serious mental disorders with
psychotic or manic symptoms (e.g., psychotic disorders, bipolar disorders, etc.), sensory
complications that would prevent exposure (e.g., visual, tactile, or auditory deficits),
epilepsy, and other medical conditions (such as pregnancy and clinical cardiac arrhythmia).
2.2. Measures
2.2.1. Pre-Post Assessment Measures
Visual Analog Scales (VAS)
• Self-reported FBI levels were assessed within the VR environment using a VAS to
determine the extent to which the patients felt the virtual body was their own body
on a scale ranging from 0 (not at all) to 100 (completely).
• Self-reported FGW levels were assessed within the VR environment using a VAS to
determine the extent to which the patients were afraid of gaining weight while owning
the virtual body on a scale ranging from 0 (not at all) to 100 (completely).
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• Self-reported anxiety levels were assessed within the VR environment using a VAS to
determine the extent to which the patients were anxious about their own body while
owning the virtual body on a scale ranging from 0 (not at all) to 100 (completely).
AB Measures
Body-related AB was measured by determining the patient’s visual fixation on their
own body. Visual fixation has been defined as an involuntary act of maintaining the gaze
on a specific spot, at least, for 100–200 ms [57]. In this study, the duration established to
define a fixation was 100 ms. The two main groups of areas of interest (AOIs) of the body
were defined based on the Physical Appearance State and Trait Anxiety Scale (PASTAS).
Specifically, the weight-related AOIs (W-AOIs) were the stomach, hips, waist, thighs, and
legs, which were individually drawn onto a two-dimensional frontal view picture of the
female or male avatar. The remaining body areas were also drawn onto the same image
and were labeled as non-weight-related AOIs (NW-AOIs).
Visual fixation was estimated from the number of fixations (i.e., the sum of the avail-
able fixations on the specified AOI group) and the total fixation time (i.e., the sum of
the fixation duration for the specified AOI group in milliseconds). Both measures are
considered reliable and provide a continuous way of assessing body-related AB. They have
been widely applied in previous studies using ET technology [58].
2.2.2. Pre-Assessment, Post-Assessment, and Three Months Follow-Up Measures
Body-related measures and other ED clinical symptomatology.
• The BMI was used as a common indicator of body fatness to assess changes in weight
in the pre-, post-, and follow-up assessments. The BMI was calculated by dividing the
patient’s weight (in kilograms) by the square of their height (in meters).
• Eating Disorder Inventory 3 (EDI-3) [59]. The EDI-3 is a widely used self-report
and standardized measure to assess symptomatology and psychological features
relevant to the development and maintenance of EDs. The third version (EDI-3)
includes 91 items classified into 12 scales, with a six-point Likert scale for each answer
ranging from 0 (never) to 5 (always). The EDI-3 questionnaire and materials have
been translated into Spanish and validated [60]. This Spanish version presents robust
validity and reliability indices (like the original version), with a Cronbach’s alpha
ranging from 0.74 to 0.96. In the current study, we only used the Body Dissatisfaction
(EDI-BD) and Drive for Thinness (EDI-DT) scales. The EDI-BD scale, with 10 items,
measures the negative subjective attitude or evaluation of one’s body or specific
body areas, including their shape, weight, and fitness. The EDI-DT assesses the
strong desire to have a thinner body and to lose weight, as reflected by the intense
concerns about the body shape or weight, the diet and the FGW. The Cronbach’s
alpha values in this study were 0.825 for the EDI-BD scale and 0.84 for the EDI-DT
scale. The fourth item of the EDI-DT scale (i.e., “I am terrified about gaining weight”)
was also used as an independent measure to determine the FGW in the pre-, post-,
and follow-up assessments.
• Physical Appearance State and Trait Anxiety Scale (PASTAS) [58]. The PASTAS is a
reliable and valid measure for the assessment of trait and state body image anxiety.
Patients had to rate, on a five-point scale ranging from 0 (never) to 5 (always), if they
felt anxious or nervous about their physical appearance, including any tension, nega-
tive thoughts, and physiological responses. Although the questionnaire comprises
two scales (weight-related and non-weight-related scales) that measure anxiety for
16 body areas, only the eight-item Weight Scale was used in this study. The scale
presents good reliability and reliability indices [61]. In the current study, Cronbach’s
alpha was 0.817.
• The Body Image Assessment Scale-Body Dimensions (BIAS-BD) [62] was used to
assess the perceptual and emotional components of BIDs. This test assesses the
discrepancy between the perceived body size and the self-determined ideal body
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size (to measure body dissatisfaction). Furthermore, it also reveals the discrepancy
between the perceived body size and the real body size (to measure body distortion).
The scale presents a range of 17 silhouettes, with different versions for women and
men. The two test–retest A–B versions were used in the pre-assessment (version A),
post-assessment (version B), and follow-up assessment (version A again). Patients
had to select the silhouette that they perceived to be the most similar to their own and
the silhouette that they would like to have. Finally, the researchers also selected the
real silhouette based on the patient’s BMI.
• The Body Appreciation Scale (BAS) [63] was used to assess positive attitudes towards
one’s own body. This 12-item scale was translated into Spanish by Jáuregui-Lobera
and Bolaños-Ríos [64]. The scale measures a single dimension of a positive body
image, which includes having a positive opinion and accepting one’s physical features,
the adoption of healthy behaviors with regards to one’s body, and the rejection of
dangerous body ideals usually displayed in social media. The BAS items are rated on
a five-point Likert scale that is averaged to obtain a final score of body appreciation,
which ranges from 0 to 60, with higher values suggesting greater body appreciation.
2.3. Technical Features
2.3.1. Hardware
All the ED Units that participated in the study had a complete VR package and power-
ful VR-ready computers equipped with high-end CPU processors (i.e., Intel i7 processors)
and powerful graphic cards (i.e., Nvidia GTX 1080) to fluently run 3D immersive virtual
environments. The whole VR system included head-mounted displays (HTC-VIVE HMD),
two different VR controllers that the patient held in their hands, and three additional
body trackers that were attached to the feet and waist of the patients. All the equipment,
including the VR-HMD, controllers, and body trackers, was used to capture the whole body
movements of the patients (full-body tracking system). Furthermore, two HTC-VIVE base
stations were placed at a considerable height, approximately two meters off the ground
(using tripods), and diagonally positioned at opposite corners of the doctor’s office, to
create a minimum play area of 2 m × 1.5 m (6 ft 6 in × 5 ft).
Finally, a second headset with incorporated ET technology (FOVE VR-HMD) was
used to detect eye movement while the patients were immersed in the VR environment
before and after the intervention. The FOVE VR-HMD uses 120 Hz infrared ET sensors,
with a resolution of 2560 × 1440 pixels and a spatial accuracy of less than one degree.
2.3.2. Software
The female and male avatars were initially designed using the software Blender v.
2.78, which is particularly useful for designing specific details of the body, such as the
clothes or the skin, and for creating a complete skeleton of the virtual avatar that can
reproduce realistic movements using a full-body tracking system. Both the female and
male avatars wore standard clothes (a white t-shirt, blue jeans, and black trainers). The
hair was covered by a gray hat to reduce any influence of hairstyle on each patient. The
avatars also wore an HMD like the patients. Finally, the height could be easily adjusted
based on the patient’s height.
The Unity 3D 5.6.1 (Unity Technologies) software was used to design the VR room,
develop the programming code, and incorporate the virtual avatars within. The virtual
environment consisted of a unique room without any furniture, except for a large mirror
on the wall placed 1.5 m in front of the patient. The patients could see their whole body
reflected in the mirror, even when they were moving.
2.4. Procedure
2.4.1. Overview
The ethics committees of the University of Barcelona (Institutional Review Board
IRB00003099) and the three hospitals that participated in this study reviewed and approved
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this study. Furthermore, the study protocol and reporting was conducted in accordance
with the statement of the Consolidated Standards of Reporting Trials (CONSORT) [65].
All the patients accepted into each of the ED units received a complete psychological,
nutritional, and medical assessment, and were diagnosed by clinical psychologists and
psychiatrists. All the ED Units used, at least, a non-structured clinical interview to as-
sess the fulfillment of the DSM-5 criteria, and, in two of them, the Mini-International
Neuropsychiatric Interview (MINI; [66]) was also used by trained clinicians.
All the ED Units offered three different ED treatment programs: an outpatient program
for patients with good treatment compliance and lower biopsychological risk, a day-patient
treatment for those whose weight restoration and eating behaviors were not improving, and
finally an intensive 24-h hospitalization program for patients with a high biopsychological
risk (i.e., very low weight).
The current study focused only on patients who attended the day patient program.
These patients underwent a multidisciplinary treatment that consisted of CBT conducted
individually and in groups, nutritional rehabilitation that aimed to improve eating patterns
and increase weight, and group counseling for their relatives. Individual CBT consisted of
a minimum of one session per week, usually two sessions per week, for both adolescent
and adult patients, each lasting 45–60 min. Adolescent patients attended the inpatient
treatment unit for 11 h a day (sleeping at home). For a more detailed description, see
Serrano-Troncoso et al. [67]. The adult patients attended the ED Unit for over 6 h a day.
Furthermore, adult patients diagnosed with a borderline personality disorder were also
treated in a specialized unit for approximately 4 h a day.
All patients were enrolled in the study at similar times after the beginning of the
day-patient program treatment. Once the study began, all the clinicians from the ED
units who had direct contact with the patients checked whether they met the inclusion
and exclusion criteria. During the first week, patients were informed of the possibility of
participating in the study. They were then enrolled during the second or third week, while
the same clinicians obtained written informed consent from all the patients included in
the study (in the case of the adolescent patients, informed consent was also obtained from
their parents or legal guardians). All the sessions were carried out by a psychologist with
previous clinical experience and a co-therapist who helped provide additional support on
some of the tasks conducted during the treatment.
As shown in Figure 1, all the patients were assessed three times: in the pre-assessment
session, after five weeks in the post-assessment session, and at follow-up three months
later. Furthermore, all the patients were randomly assigned to one of the two groups: the
experimental group receiving VR-based body exposure alongside the usual CBT or the
control group receiving the usual treatment only.
Randomization of the sample was conducted using the AleatorMetod.xls software [68]
(Ramos-Alvarez, 2005) before the start of the study.
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using a frontal and lateral perspectives, with the silhouette of the real-size avatar matched 
to the pictures. While the virtual avatar was being created, the patients had to complete 
all the pre-assessment questionnaires. The patients were then immersed in the VR 
environment, in which they underwent visuomotor and visuo-tactile stimulation 
procedures, adapted from previous studies [69–72], to elicit FBI over the virtual body. 
Both procedures lasted three minutes, and at the end, the FBI, body-related anxiety and 
the FGW that they were experiencing at that moment were assessed using the VAS. For 
an illustrative description of the procedure, see Figure 2. 
Figure 1. Participant flow throughout the study and the experi ental design of the study.
2.4.2. Pre-Assessment, Post-Assessment, and Follow-Up Sessions
The pre-assessment session lasted approximately one hour. Since the procedures
conducted in the pre-assessment (photography, visuomotor, and visuo-tactile stimulations
and ET assessment task procedures) have been described in a previous study by our group,
this section has been summarized. For a detailed description, see [69].
In the first session, any doubts or questions that the patients had about the first
session or the whole treatment were addressed. The patients were also informed about the
confidentiality of the data and were provided with a specific identification code.
The first step as to create the virtual avatar. photograph of the patient as taken
si g a fro tal and lateral perspectives, with the silhouette of the real-size avatar matched to
the pictures. While th virtual avat r w s being created, the pati nts had to complete all th
pre-assessment questionnaires. The patients were then immersed in the VR environment,
i which they u derwent visuomotor and visuo-tactile stimulation pro edures, adapted
from previous studies [69–72], to elicit FBI over the virtual body. Both procedures lasted
three minutes, and at the end, the FBI bo y-related anxiety and the FGW that they were
experiencing at that moment w re assessed using the VAS. For an illustrative description
of the procedure, see F gure 2.
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The last step consisted of conducting the ET task. The previous headset (HTC-VIVE
HMD) was replaced with the new ET FOVE VR headset. After a brief calibration and
validation procedure, the patients were exposed to the same virtual environment as before.
They were asked to observe their virtual body reflected in the mirror, while their spontaneus
gaze was tracked for 30 s, as done in previous studies [73,74]. As a cover story, they were
told that the full-body tracking system (i.e., body trackers and controllers) was being
recalibrated and that it was important that they remained still during the process.
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2.4.3. VR Body Exposure Sessions (Experimental Group)
Before starting the treatment, the clinicians responsible for each patient proposed a
healthy BMI target for the patients to reach. The target BMI was calculated by considering
the patient’s age and their BMI prior to the onset of the disorder. Therefore, the target BMI
was not the same for all the patients, but tailored to each case.
Exposure sessions w re conducted weekly, fac t ace, lasting approximately 60 min.
In the first session, the patients were exposed to a virtual body with their real-size silhouette
and BMI (Figure 1). Then, small BMI increases were applied to the virtual body over
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successive exposure sessions, until the healthy BMI target was finally reached. For instance,
an adult patient with a BMI of 17 kg/m2 in the first session who was aiming to reach a
healthy BMI of 19 kg/m2 had to undergo small BMI increases of 0.5 kg/m2 over the four
subsequent sessions.
Before starting each body exposure session, the clinicians answered any questions that
the patients might have had about the current or past sessions. Once in the VR environment,
each session was initiated by conducting the visuomotor and visuo-tactile stimulation
procedures to induce the FBI over the virtual body. The VAS assessing the FBI level was
also applied. The body exposure task began by asking the patients to orally report their
thoughts and feelings about most of the body parts of their virtual body (starting from
the head, shoulders, arms, hands, chest, stomach, waist, hips, thighs, lower legs, and then
the feet). This task allowed the patients to spread their visual attention across the whole
virtual body.
At the same time, their anxiety levels were monitored, using a VAS, every two minutes
during the exposure session. The body exposure session was ended once the anxiety levels
had been reduced by 40% compared to the initial anxiety level or once the duration of the
session had elapsed. The last 5 min of the session were dedicated to helping the patients
reduce their anxiety or any other sort of discomfort that they might have experienced
during the body exposure task. The patients were immersed in relaxing VR environments
(i.e., waterfalls, forests, or beaches) for debriefing.
The aim of the intervention was to continue to the next item in the hierarchy (i.e., a
BMI increase). However, for the patients who had not reduced their anxiety level by 40%
during the session, they were exposed again to the same avatar in the following session.
2.5. Statistical Analyses
The Open Gaze and Mouse Analyzer (OGAMA) software was used to prepare the ET
data. For further details on this procedure, see [69].
All the subsequent statistical analyses were performed with SPSS version 24. First,
Fisher’s exact test for categorical variables and independent-samples t-test for continuous
variables were conducted to assess whether there were any significant group differences in
any of the demographic and clinical measures assessed at baseline/pre-assessment. Then,
mixed between (group)–within (pre-post-follow-up assessment times) analyses of variance
(ANOVA) were conducted for the BMI and all the ED measures (primary measures). Fur-
thermore, mixed between (group)–within (pre-post-assessment times) analyses of variance
(ANOVA) were conducted for AB measures and the VAS scores (secondary measures).
Regarding the assumptions of the tests, homogeneity of variance was met for most
of the variables (p > 0.05), as demonstrated by Levene’s test. The sphericity test (p > 0.05)
was also met for almost all the variables. Although some of the variables (e.g., the BMI,
EDI-DT-FGW, and some of the VAS scores) were not normally distributed, as determined by
the Shapiro–Wilk test, it was decided to run the tests anyway, since ANOVA is considered a
reasonably robust test to deviations from normality [75]. Finally, two outliers were detected
in the BMI, one of which affected the other measures as well, which was identified by the
inspection of a boxplot. After conducting the analyses with and without the outliers, it was
decided that they would be kept in the analyses, since the results did not vary significantly.
3. Results
3.1. Descriptive Results
The patients had a mean age of 18.63 years (SD = 6.78, age range: 13–44 years), a
mean BMI of 17.48 kg/m2 (SD = 1.12, BMI range: 14.25–18.95 kg/m2), and were mainly
female (31/35, 88.57%). Moreover, 60% of them were adolescents (21/35), while 40% were
adults (14/35). The other demographic and clinical characteristics of the groups are shown
in Table 1.
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X2 (df) t-Test (df) p Value
Age. Mean years (SD) 18.25 (1.30) 19.21 (1.78) N/A 0.419 0.68
Group age, n (%) 0.551 (1) N/A 0.5
Adolescents 9 (56.25) 12 (63.16)
Adults 7 (43.75) 7 (36.84)
BMI a, mean kg/m2
(SD)
17.30 (1.06) 17.54 (1.27) N/A 0.513 0.44
Sex, n (%) 0.033 (1) N/A >0.99
Women 14 (87.5) 17 (89.47)
Men 2 (12.5) 2 (10.52)
Main diagnosis, n (%) 0.285 (2) N/A 0.7
AN-R type b 13 (81.3) 14 (73.7)
AN-P type c 3 (18.8) 5 (26.3)
Comorbid diagnosis, n N/A N/A N/A
GAD d 1 0
MDD e 1 1
PDD f 1 0
BPD g 2 2
PTSD h 1 0
Anxiety NOS i 1 1
Depression NOS 0 2
Number of comorbid diagnosis, n (%) 0.810 (2) N/A 0.84
0 10 (68.6) 14 (77.4)
1 5 (31.3) 4 (21.1)
2 1 (6.3) 1 (5.3)








Note: N/A: not applicable. a BMI: body mass index, b AN-R: anorexia nervosa restrictive subtype, c AN-P:
anorexia nervosa purgative subtype, d GAD: generalized anxiety disorder, e MDD: major depressive disorder,
f PDD: persistent depressive disorder, g BPD: borderline personality disorder, h PTSD: posttraumatic stress
disorder, I NOS: not otherwise specified.
Fisher’s exact test and independent-samples t-test showed that there were no signif-
icant differences between the groups at baseline in any of the demographic and clinical
variables, including medication, main diagnosis, and the number of comorbid diagnoses.
Furthermore, independent-samples t-test analyses showed that there were no statisti-
cally significant group differences (p > 0.05) in the pre-assessment session, in any of the
clinical measures.
Figures 3 and 4 show the means and standard errors of the mean of all the clinical
measures for the experimental and control groups at the different assessment times.
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the VAS scores (see Figure 3a–c, respectively). The results indicated a lack of statistically 
significant interactions between the group and assessment time (p > 0.05) for FBI (VAS-
FBI) and body anxiety (VAS-A). However, there was a main effect of time on FBI (F (2, 96) 
= 3.297, p = 0.044, partial η2 = 0.147). Overall, despite no significant group differences, 
individuals in the experimental group reported higher FBI levels in the post-assessment 
session than in the pre-assessment session, while the control group reported similar FBI 
levels before and after the intervention. 
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fixation Time (3d) and Number of Fixations (3e). Error bars represent standard errors of the mean. Note: BMI = Body mass
index. * p values < 0.05.
3.2. FBI, Body Anxiety and FGW VASs
Two-way mixed ANOVA was conducted for FBI, body anxiety, and the FGW using the
VAS scores (see Figure 3a–c, respectively). The results indicated a lack of statistically signif-
icant interactions between the group and assessment time (p > 0.05) for FBI (VAS-FBI) and
body anxiety (VAS-A). However, there was a main effect of time on FBI (F (2, 96) = 3.297,
p = 0.044, partial η2 = 0.147). Overall, despite no significant group differences, individuals
in the experimental group reported higher FBI levels in the post-assessment session than in
the pre-assessment session, while the control group reported similar FBI levels before and
after the intervention.
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Regarding the FGW, there was a marginally significant interaction between group and
assessment time (F (1, 26) = 3895, p = 0.059, η2 = 0.130). Follow-up analyses showed that
the FGW scores did not differ between the two groups (p > 0.05) in the pre-assessment, but
there were significant group differences in the post-assessment (F (1, 26) = 5611, p = 0.028,
partial η2 = 0.173), with a high effect size according to Cohen (1998). The experimental
group reported significantly lower FGW values compared to the control group (MD = 23.21,
SE = ±9.94).
3.3. Body-Related Attentional Bias
Two-way mixed ANOVA was conducted for both attentional bias measures. The
results indicated a lack of statistically significant interactions between the group and
assessment time for the total fixation time (F (1, 21) = 1025, p = 0.323, partial η2 = 0.047) and
the number of fixations (F (1, 21) = 2782, p = 0.110, partial η2 = 0.117).
Although there were no statistically significant group*time interactions, there was a
clear trend at post-assessment in which patients in the experimental group showed lower
AB towards W-AOIs than those in the control group, who showed higher AB towards
W-AOIs (total fixation time: MD = 6011, SE = ±3703; number of fixations: MD = 14.39,
SE = ±7.69). For illustrations, see Figure 3d,e.
3.4. ED Measures (Pre-Assessment, Post-Assessment, and Three-Month Follow-Up)
Two-way mixed ANOVA was conducted for all the ED measures. There were signifi-
cant interactions between group and assessment time for body distortion (F (2, 50) = 7.763,
p = 0.002, partial η2 = 0.218), body dissatisfaction assessed with the BIAS-BD ques-
tionnaire (F (2, 52) = 5.084, p = 0.033, partial η2 = 0.123), and body dissatisfaction as-
sessed with the EDI-BD (F (2, 52) = 4.425, p = 0.017, partial η2 = 0.145). Furthermore,
marginally significant interactions between group and time were found for body appre-
ciation (F (2, 52) = 3.065, p = 0.057, partial η2 = 0.104) and FGW, as assessed by the EDI-
DT-FGW item (F (2, 50) = 2.671, p = 0.078, partial η2 = 0.097). Follow-up analyses in all
these measures showed that there were significant group differences on FGW at the post-
assessment (F (1, 25) = 4.626, p = 0.041, partial η2 =.156), and there were significant group
differences at follow-up for body distortion (F (1, 25) = 5.264, p = 0.030, partial η2 = 0.174),
body dissatisfaction assessed with the EDI-BD (F (1, 26) = 4.320, p = 0.048, partial η2 = 0.142),
and FGW (F (1, 25) = 5.584, p = 0.026, partial η2 = 0.186). As shown in Figure 4a,b,d, after
the intervention and especially at follow-up, the experimental group reported significantly
lower levels of FGW, body distortion, and body dissatisfaction compared to the control
group. Despite the experimental group showed a more pronounced descrease in body
dissatisfaction scores assessed with the BIAS-BD (Figure 4c), and a more pronounced
increase in body appreciation values (Figure 4g) compared to the control group, group
differences did not reach statistical significance (p > 0.05) in the post-assessment session or
at follow-up.
Finally, there were no statistically significant group*time interactions (p > 0.05) for any
of the other ED measures assessed (BMI, drive for thinness and body anxiety). However,
there was a main effect of assessment condition on BMI (F (1, 60) = 11.407, p ≤ 0.001,
partial η2 = 0.275), body anxiety (F (1, 52) = 6573, p = 0.003, partial η2 = 0.202), and drive
for thinness (F (1, 52) = 3.508, p = 0.037, partial η2 = 0.119). Post-hoc tests (pairwise
comparisons) were conducted, and results showed that regardless of the group, there were
significant differences (p < 0.05) between pre- and post-assessment in BMI (MD = −0.45,
SE = 1.12, p = 0.002), and between pre-assessment and follow-up in BMI (MD = −0.69,
SE = 1.66, p = 0.001) and body anxiety levels (MD = 5.18, SE = 1.54, p = 0.007). There were
also marginally significant differences between pre-assessment and follow-up (MD = 2.28,
SE = 1.35, p = 0.068) for drive for thinness. As can be seen in Figure 4e,f,h, regardless of the
group, there was a continuous decrease in symptomatology in the post-assessment and at
follow-up for BMI, body anxiety, and drive for thinness. Again, this decrease seemed to be
more pronounced in the experimental group.
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3.5. Age as a Predictor of a Worse Treatment Outcome at Post-Assessment
Based on the descriptive data, adult patients tended to report greater ED symptoma-
tology at post-assessment, including a greater FGW, than the adolescent patients. This was
especially noticed in the experimental group, suggesting that the VR intervention might
be more effective in young patients than in adults. Thus, post-hoc simple linear regres-
sion analyses were run in each group separately to assess whether age was a significant
predictor of a worse clinical outcome.
In the control group, linear regression analyses showed that age did not significantly
(p > 0.05) predict greater ED symptomatology, including the FGW, in any of the measures
assessed. However, a higher age did significantly predict lower values of FBI after the
intervention (F (1, 14) = 7.191, p = 0.019) that accounted for 35.6% of the explained variability.
In the experimental group, age was a significant predictor of higher values of body
dissatisfaction assessed with the EDI-3 (F (1, 14) = 5.682, p = 0.033), which accounted for
30.4% of the explained variation. Furthermore, a higher age also significantly predicted
lower FBI levels (F (1, 13) = 6.678, p = 0.024) that accounted for 35.8% of the explained
variation. For an illustration see Figure 5a,b.
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4. Discussion
As previously stated, AN is one of the most serious EDs, with very worrying rates
of mortality compared to other disorders [76] and an increasingly higher prevalence of
diagnoses in early adolescence [3,5]. Thus, focusing on new interventions that aim to
reduce the core fears (such as the FGW) and other body-related concerns is essential
to improve evidence-based therapy in AN. The current study provides a new insight
and encouraging findings in the field of exposure-based therapies in AN. Based on our
results, the addition of body exposure therapy through VR (experimental group) to the
usual treatment for AN was more effective than usual treatment only (control group),
particularly for the FGW and BIDs. This intervention was effective in reducing FGW levels,
as observed by significant group differences in the post-assessment and follow-up, in
which the experimental group showed a significantly higher reduction in FGW scores
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than the control group. Furthermore, this intervention was also effective in reducing BIDs.
Indeed, after the intervention and especially at follow-up, the experimental group reported
significantly lower levels of body distortion and body dissatisfaction than the control group.
Furthermore, similar tendencies (although not significant) were found among all the other
measures, in which the experimental group showed a more pronounced decrease in ED
symptomatology and a higher increase in the BMI and body appreciation values compared
to the control group. These tendencies were maintained at the three-month follow-up.
Finally, preliminary evidence suggested that age was a significant predictor of a worse
clinical outcome after the intervention.
The current study is the first to develop a tailored, controlled, and empirically vali-
dated VR-based body exposure intervention to help patients with AN confront their core
fear, the FGW. The current results also provide further evidence supporting the findings
from a preliminary case report also conducted by our group [54]. Furthermore, our results
suggest that there was a continuous weight restoration in both groups after the intervention
and after three months, being slightly higher in the experimental group. These results are
important, since weight restoration is considered a robust predictor of remission from AN
and is necessary for recovery [77].
Our results are also in line with those of previous studies that used imaginal exposure
to reduce the FGW and other ED symptomatology in patients with EDs [55,56]. As previ-
ously noted, virtual or imaginal exposure-based therapies are an innovative and interesting
way of helping patients with AN confront situations or fears that is difficult to achieve with
other techniques. For instance, these techniques can be used to modify the content of the
negative consequences associated with the FGW that patients with AN usually report.
The clinical impact of the FGW and its associated negative consequences in patients
with AN are well-known, being directly associated with other ED symptoms [11,14].
Indeed, several studies have claimed that tailored behavioral interventions targeting the
FGW in AN are effective in reducing other ED symptoms [10,26–28]. Our results might
provide evidence supporting this approach. Even though significant group differences
were found for only a few measures (BIDs), there was a more pronounced reduction in ED
symptomatology in the experimental group than in the control group in all the measures
assessed in the post-asssessment and at follow-up.
Similarly, there was a significant decrease in BIDs, including body distortion and body
dissatisfaction levels, particularly among the patients in the experimental group. These
findings are particularly important, since patients with AN usually present persistent
cognitive and emotional disturbances in the way they perceive their body weight or
shape [16]. Moreover, previous research suggests that patients with long-term BIDs have a
higher risk of future relapse and more negative outcomes after treatment [78].
Our results also support previous studies that used in-vivo body exposure procedures
(i.e., MET) to reduce body dissatisfaction among patients with EDs [79] and patients with
AN [36]. However, the previous studies exposed individuals to their real body over a
prolonged period of time to reduce negative body-related responses (such as a negative
mood or body dissatisfaction) through habituation [36,37,80], while the current study went
one step further and first exposed patients to their real-size virtual body, and then applied
a gradual increase in their BMI over successive sessions until they owned a virtual avatar
with a healthy BMI. Thus, VR technology and embodiment-based procedures allow us to
go further and help patients with AN reduce their negative body-related responses, such
as body dissatisfaction, not only when they are exposed to their real body (as has been
previously done in MET), but also when they are exposed to a virtual representation of
their own body with a certain amount of weight gain.
Patients in the experimental group also showed a significant reduction in body dis-
tortion levels at follow-up. These findings are important, since body distortion is one of
the key components targeted in the treatment of AN and an improvement is critical for a
better long-term outcome among adolescents with AN [81]. However, there are only a few
treatment approaches directly targeting body distortion or assessing changes before and
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after usual inpatient treatment in AN [82]. One key aspect of using a VR embodiment-based
procedure is that it allows individuals to realistically experience a virtual body as their
own body, eliciting the same sensorial responses or activating the same implicit or explicit
multisensory representations of their own body [83,84]. Moreover, the modification of the
size or shape of the virtual body can be used to improve the disturbed representation of
the body, as has been reported in patients with AN [46,52] and patients with other mental
health issues [84]. The current study is the first to elicit changes in body distortion after
several repeated treatment sessions, in contrast to previous studies that reduced body
distortion levels in patients with AN after one single session of exposure to a standard
healthy body [46,52]. Furthermore, the weight gain of their avatar was spread across the
virtual body that initially represented the patient’s silhouette and BMI. Thus, it allowed
more accurate and realistic weight increases over successive sessions. This could have
been a key factor in helping patients internalize the changes in their own real bodies after
the intervention. Indeed, our results on the FBI levels support this. FBI levels in the
experimental group were notably higher in the post-assessment than in the pre-assessment,
while no changes were observed in the control group. A previous study demonstrated that
higher body distortion levels significantly predicted lower FBI levels among patients with
AN [69]. Thus, this relationship might be bidirectional, meaning that regarding the virtual
body progressively more as their own body might have helped patients with AN correct
their biased perception of their own body size, thereby reducing body distortion levels.
After the intervention, patients in the experimental group showed lower AB towards
W-AOIs than those in the control group, who showed higher AB towards W-AOIs. These
tendencies, even if not significant, suggested that body-related AB in patients with AN
might be modified by a VR-based body exposure intervention. A key aspect in under-
standing these results might rely on the procedure conducted in the experimental group, in
which patients attended at different parts of the virtual body (from the head to the shoes),
while they were asked to orally express what they thought and felt about those body areas.
Thus, since patients had to look at those parts for a certain amount of time in every session,
this could have reduced their AB towards weight-related body areas, leading the patients
to spread their attention more equally among all the body parts. Indeed, similar procedures
have been conducted in previous studies with women presenting high body dissatisfac-
tion, in which a short-term AB towards (un)attractive body areas was induced to reduce
body dissatisfaction levels among healthy women [85–87]. However, to the best of our
knowledge, the current study is the first to specifically assess body-related AB among AN
patients before and after a body exposure-based intervention. These results, nevertheless,
should be carefully considered, since eye-gaze behavior was not properly controlled during
the sessions (e.g., by using ET devices) and the sample size was small (only 23 patients
were assessed using ET devices before and after the intervetion). Modifing body-related
AB is an important target in ED treatments [88]. Several studies suggest a bidirectional
relationship between body-related AB and other body-related concerns, especially body
dissatisfaction in patients with EDs [21,58] and also among adolescents with AN [23].
Finally, preliminary evidence suggested that age only emerged as a significant predic-
tor of higher body dissatisfaction levels post-intervention in the experimental group. This
indicated that the VR exposure intervention was more effective in reducing body dissatis-
faction among young patients compared to adult patients. Indeed, adult patients reported
lower FBI levels than younger patients, specifically in the post-assessment, which could
be a key aspect to target in order to reduce other symptoms such as body dissatisfaction
and improve overall treatment efficacy. In fact, a previous study that used a digital variant
of the RHI found that age was directly associated with a reduced perceptual illusion over
the fake hand [89]. Thus, similar results could be expected when the ownership illusion is
elicited over a whole virtual body. Furthermore, our results are in line with those of another
study that found that it was more difficult to elicit changes in body representations among
adults compared to young healthy participants [90]. The current study, thus, expands
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previous findings in a clinical sample of patients with AN, suggesting that future studies
should offer tailored interventions separately to adolescents and adults with AN.
The current study had some limitations that should be addressed in future studies.
Regarding methodological limitations, the sample size was small and, thus, the current
findings should be considered carefully. Although a prior power analysis suggested the
need for a higher sample size (i.e., 54 patients), it was not possible to achieve this figure.
Furthermore, due to the small sample size, data from both adults and adolescents with
AN were considered together in the statistical analyses. However, preliminary evidence
indicated that age was significantly associated with a worse clinical outcome in the ex-
perimental group. Consequently, future research should assess the efficacy of the current
intervention separately for adults and adolescents with AN.
Statistical analyses were conducted without controlling for some key variables, such
as the sub-type of AN, illness duration, other mental health comorbidities, and pharmaco-
logical treatments. In addition, the current study only had a three-month follow-up, which
might not have been long enough to observe the complete development of ED symptoms
over a long period of time or to assess future relapses among patients. Future studies could
attempt to replicate or extend the current findings with a longer follow-up assessment (for
instance, one-year follow-up). In addition, all our patients attended day patient programs,
and so it may not be possible to generalize our results to more severe cases of AN who
usually attend intensive 24 h-hospitalization programs. Finally, although the drop-out rates
of the current study are low, particularly among patients in the experimental group (where
only two patients abandoned), it would have been useful to complement this information
with a more accurate assessment of satisfaction with treatment among patients.
The other limitations were associated with the AN-VR-BE software. These limitations
should be considered and improved in the future updates of the software. Despite realisti-
cally reproducing a virtual body with the same silhouette and BMI as that of the patient’s
body, other important features of the general appereance (e.g., the general outfit, the tone of
the skin, the hairstyle, etc.) could not be simulated. Furthermore, the adult patients usually
reported that the virtual body seemed “too young” for them, which could also explain the
lower FBI levels found among them compared to the adolescent patients. A possible way
to improve the realism of the avatar is by using 3D scans and biometric avatars, which
allow the personalization of virtual bodies with all the features of the individual [70]. Thus,
future studies can reproduce current findings using highly realistic virtual bodies and
different virtual environments to generalize the current findings to other highly relevant
everyday life situations (e.g., dressing rooms, swiming pools, beaches, etc.).
Although evidence-based treatments for AN have significantly improved in quality
and amount in the last decade, further research is still needed to improve the interventions
for AN, including CBT, which often achieves modest results [4]. The randomized clinical
trial presented in this study showed that a VR exposure therapy can enhance the effec-
tiveness of the usual day-patient treatment for AN and help patients with AN confront
their core FGW. Specifically, our results showed that patients in the experimental group
showed significantly reduced FGW and BID levels than those in the control group after
the intervention and at follow-up. Furthermore, promising non-significant trends were
observed for other ED measures, such as the BMI, body anxiety, drive for thinness, body
appreciation and body-related AB.
The use of VR technology might improve research and clinical practice in AN by
providing new tools to help patients confront their core fears (i.e., food- or weight-related
cues) and improve their emotional, cognitive, and behavioral responses to their body image
as well as other important ED symptoms. Future research might test the implications of
the current findings in more severe cases of AN. As stated above, the use of in-vivo
mirror and body exposure techniques in severely emaciated AN patients is controversial,
as it may elicit habituation toward extremely low weights. Future VR body exposure
interventions should try to provide innovative solutions to this issue. Rather than helping
patients with AN to habituate toward their own body, this technology might be used
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to help them gradually cope with their core fears, such as weight gain. However, some
important challenges remain, for example, improving adherence at this early stage of the
treatment, and adapting a specific (VR) body exposure procedure in which patients with
severe AN do not have to stand for a long period of time. Furthermore, combining VR
and ET technologies might lead to new possibilities in the field of body-related AB in EDs.
For example, patients could be immersed in VR environments that simulate everyday
life situations that are emotionally salient for them (i.e., expose their body in a gym, a
beach, a pool, etc.), with their gaze patterns continuously measured using ET devices.
This could provide an objective measure of how patients with EDs or AN spontaneously
interact with the clinical stimuli (e.g., self vs. other avatars with different body sizes or
faces expressing positive vs. negative emotions) within the VR environment. Additionally,
clinical interventions could use our findings to design specific interventions that aim to
retrain dysfunctional body-related AB among patients with AN or other EDs.
To conclude, the current study presents an innovative and pioneering VR body expo-
sure procedure that could have promising future applications in the field of EDs and BIDs.
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